Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Coffee consumption habits impact the risk of mild cognitive impairment

  • Link between intestinal bacteria, depression found

  • National study of deep brain stimulation for depression fails to demonstrate efficacy

  • Specific cardiovascular risk factors may predict Alzheimer's disease

  • DeepBind predicts where proteins bind, uncovering disease-causing mutations

  • Narrowing in on pituitary tumors

  • Blood markers identify women at risk for postpartum depression

  • Sleep makes our memories more accessible, study shows

  • Insulin resistance increases risk for Alzheimer's disease, study finds

  • Researchers identify neural signature of tunnel vision

  •